The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Julie Brahmer named director of thoracic oncology at Johns Hopkins Kimmel Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

JULIE BRAHMER was named director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center.

Brahmer will oversee a $35 million investment in the program and the opening of the new Thoracic Center of Excellence at Johns Hopkins Bayview Medical Center, as well as clinical trials and research focused on lung and esophageal cancer and mesothelioma.

Brahmer has been a faculty member at Johns Hopkins since 2001. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group’s Thoracic Committee and Cancer Prevention Steering Committee. A founding board member of the National Lung Cancer Partnership, now known as Free to Breathe, she currently serves as a member of its Scientific Executive Committee.

She also sits on the Lung Cancer Research Foundation’s Medical Advisory Board, Uniting Against Lung Cancer’s Medical Committee and LUNGevity’s Scientific Advisory Board.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account